Knights of Columbus Asset Advisors LLC Buys New Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

Posted by Brenda Bartman on May 29th, 2026

Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,314 shares of the company’s stock, valued at approximately $1,104,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RYTM. EverSource Wealth Advisors LLC raised its holdings in shares of Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares during the period. Optiver Holding B.V. increased its position in Rhythm Pharmaceuticals by 65.2% during the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after purchasing an additional 144 shares in the last quarter. SBI Securities Co. Ltd. increased its position in Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares during the period.

Rhythm Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:RYTM opened at $92.98 on Friday. The company has a market capitalization of $6.37 billion, a price-to-earnings ratio of -29.71 and a beta of 1.94. The company has a 50 day moving average of $87.37 and a two-hundred day moving average of $97.30. Rhythm Pharmaceuticals, Inc. has a 52-week low of $60.06 and a 52-week high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.03. The business had revenue of $60.11 million for the quarter, compared to analysts’ expectations of $55.78 million. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The business’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.81) earnings per share. On average, equities analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -3.18 earnings per share for the current year.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer owned 160 shares in the company, valued at $14,329.60. The trade was a 97.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Bank of America reduced their price target on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Canaccord Genuity Group raised their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 21st. Citizens Jmp decreased their price target on shares of Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating for the company in a research report on Tuesday, March 17th. Finally, HC Wainwright cut their price objective on Rhythm Pharmaceuticals from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $131.81.

Read Our Latest Analysis on Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Company Profile

(Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.